Related Experiment Videos
Clinical aspects of local and regional tumor therapy with 188Re-RC-160
H Bender1, P O Zamora, B A Rhodes
1Department of Nuclear Medicine, University of Bonn, Germany.
Abstract:
Somatostatin-receptors have been found to be overexpressed in a variety of neuro-endocrine and epithelial cancers. While the introduction of a long-acting somatostatin-analogue, octreotide, exerted mainly anti-cancer activity in neuro-endocrine tumors, no convincing results have been demonstrated in other cancers. RC-160, another somatostatin-analogue has been selected because of its high receptor affinity and its anti-cancer activity. 188Re is a generator produced radionuclide with favourable gamma and beta-emission, allowing diagnostic and therapeutic application. The results of in vivo biodistribution and therapeutic outcome following systemic, intralesional and intracavitary application in animal studies employing 188Re-RC-160 are summarized. Safety considerations, dosimetry estimates and applicable indications are outlined. The clinical impacts of this radiopharmaceutical in cancer management are discussed.
Insights
This study explores the potential of 188Re-RC-160, a novel somatostatin-analogue, for cancer therapy. Animal studies show promising biodistribution and therapeutic outcomes, suggesting its clinical impact in managing various cancers.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical therapy
Background:
- Somatostatin receptors are overexpressed in neuroendocrine and epithelial cancers.
- Octreotide, a somatostatin analogue, shows anti-cancer activity mainly in neuroendocrine tumors.
- RC-160, a high-affinity somatostatin analogue, exhibits anti-cancer properties.
Purpose of the Study:
- To evaluate the in vivo biodistribution and therapeutic efficacy of 188Re-RC-160.
- To assess the safety, dosimetry, and clinical applicability of 188Re-RC-160 in animal models.
- To discuss the potential clinical impact of 188Re-RC-160 in cancer management.
Main Methods:
- In vivo biodistribution studies in animal models.
- Therapeutic outcome assessment following systemic, intralesional, and intracavitary administration of 188Re-RC-160.
- Evaluation of safety parameters and dosimetry estimates.
Main Results:
- Summarized in vivo biodistribution data for 188Re-RC-160.
- Demonstrated therapeutic outcomes in animal studies across different administration routes.
- Outlined safety considerations and dosimetry estimates for 188Re-RC-160.
Conclusions:
- 188Re-RC-160 shows potential as a radiopharmaceutical for cancer therapy.
- Further clinical investigation is warranted to determine its full impact on cancer management.
- The study provides a basis for the clinical application of 188Re-RC-160.